# MEI Pharma

Source: https://onco.cc/companies/mei-pharma/  
OnCo record `mei-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MEI Pharma is a San Diego company whose PI3K-delta inhibitor zandelisib for follicular lymphoma was dropped in 2022 after the FDA signalled it would need a randomised trial, following the class-wide safety review of PI3K inhibitors.

## Summary

MEI Pharma, listed on Nasdaq, developed zandelisib, an intermittently dosed PI3K-delta inhibitor partnered with Kyowa Kirin, for relapsed follicular and marginal zone lymphoma; it reached the phase 3 COASTAL trial before the FDA's 2022 reassessment of PI3K inhibitors in blood cancers led the partners to stop US development. The company also studied voruciclib, a CDK9 inhibitor, in acute myeloid leukaemia, and later wound down its pipeline. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: MEI Pharma, Inc.
- Tags: ctgov-sponsor
- HQ: San Diego, CA
- Type: biotech
- Website: https://www.meipharma.com

## Sources

- Official website: https://www.meipharma.com
- ClinicalTrials.gov: trials led by MEI Pharma: https://clinicaltrials.gov/search?lead=MEI%20Pharma

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [PI3K delta (PIK3CD)](https://onco.cc/targets/pik3cd/)
- companies: [Kyowa Kirin](https://onco.cc/companies/kyowa-kirin/)

---
JSON: https://onco.cc/api/v1/entities/mei-pharma.json